All In Biotech

Drug Trial Radar · NCT05995535

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

112

Actual

Start

Sep 1, 2024

Primary completion

Aug 31, 2026

Study completion Aug 31, 2026

Sponsor

Lead sponsor
University of PennsylvaniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal.

Conditions

  • Opiate Withdrawal Syndrome
  • Opioid Use

Interventions

  • LFX/PGBDrug

    lofexidine tablets 0.18mg tabs pregabalin capsules 100mg and 25mg

  • LFX/PLA-PGBDrug

    lofexidine tablets 0.18mg tabs pregabalin capsules 0mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjective Opioid Withdrawal Scale (SOWS) scoresTime frame: 10 days per subject, through study completion (N=150)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Mountain Manor Treatment Center

    Baltimore, Maryland

  • University of Pennsylvania, Treatment Research Center

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.